Viral Conjunctivitis - Pipeline Review, H2 2018

Viral Conjunctivitis - Pipeline Review, H2 2018

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis - Pipeline Review, H2 2018, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.

Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 1 and 6 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Viral Conjunctivitis - Overview
Viral Conjunctivitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Viral Conjunctivitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Viral Conjunctivitis - Companies Involved in Therapeutics Development
Adenovir Pharma AB
NanoViricides Inc
Panoptes Pharma GesmbH
Shire Plc
Starpharma Holdings Ltd
Viral Conjunctivitis - Drug Profiles
APD-209 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-514 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EKCCide-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INV-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranpirnase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-640 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Viral Conjunctivitis - Dormant Projects
Viral Conjunctivitis - Discontinued Products
Viral Conjunctivitis - Product Development Milestones
Featured News & Press Releases
May 13, 2013: Starpharmas Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment
Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
May 05, 2010: Foresight Biotherapeutics, Inc s Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Viral Conjunctivitis, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Viral Conjunctivitis - Pipeline by Adenovir Pharma AB, H2 2018
Viral Conjunctivitis - Pipeline by NanoViricides Inc, H2 2018
Viral Conjunctivitis - Pipeline by Panoptes Pharma GesmbH, H2 2018
Viral Conjunctivitis - Pipeline by Shire Plc, H2 2018
Viral Conjunctivitis - Pipeline by Starpharma Holdings Ltd, H2 2018
Viral Conjunctivitis - Dormant Projects, H2 2018
Viral Conjunctivitis - Discontinued Products, H2 2018

List Of Figures


Number of Products under Development for Viral Conjunctivitis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

2018 Global Ebola Viral Vaccine Industry Report - History, Present and Future

The global market size of Ebola Viral Vaccine is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the

USD 4000 View Report

Viral Respiratory Tract Infection Global Clinical Trials Review, H2, 2018

Viral Respiratory Tract Infection Global Clinical Trials Review, H2, 2018Its clinical trial report, Viral Respiratory Tract Infection Global Clinical Trials Review, H2, 2018 provides an overview of Viral Respiratory Tract

USD 2500 View Report

Allergic Conjunctivitis - Pipeline Review, H2 2018

Allergic Conjunctivitis - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Allergic Conjunctivitis - Pipeline Review, H2 2018, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline

USD 2000 View Report

Bacterial Conjunctivitis - Pipeline Review, H2 2018

Bacterial Conjunctivitis - Pipeline Review, H2 2018The latest Pharmaceutical and Healthcare disease pipeline guide Bacterial Conjunctivitis - Pipeline Review, H2 2018, provides an overview of the Bacterial Conjunctivitis (Ophthalmology) pipeline

USD 2000 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available